Clinical trial
Zevalin-beam for Aggressive Lymphoma
NCT00491491 · Sheba Medical Center, Other · Completed
Key facts
| NCT number | NCT00491491 |
|---|---|
| Title | Zevalin-beam for Aggressive Lymphoma |
| Official title | SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma |
| Lead sponsor | Sheba Medical Center, Other |
| Collaborators | City of Hope Medical Center Amsterdam UMC, location VUmc University of Göttingen |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | ibritumomab tiuxetan, BEAM chemotherapy and autologous stem-cell transplantation |
| Enrollment | 60 |
| Start date | Jun 1, 2007 |
| Primary completion | Feb 1, 2015 |
| Completion | Feb 1, 2015 |
| First posted | Jun 26, 2007 |
| Last update posted | Aug 31, 2020 |
| Countries | Germany, Israel, Netherlands, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: